var data={"title":"Oseltamivir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oseltamivir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6690?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">see &quot;Oseltamivir: Drug information&quot;</a> and <a href=\"topic.htm?path=oseltamivir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oseltamivir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50907063\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=12662\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=12662\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204115\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tamiflu</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204116\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tamiflu</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049056\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Neuraminidase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444085\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Influenza, treatment:</b> <b>Note:</b> Treatment should ideally begin within 48 hours; however, initiation after 48 hours may decrease mortality or duration of illness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Premature neonates: Limited data available: GA: 24 to 37 weeks: Oral: 1 mg/kg/dose twice daily; duration not determined. This dose is expected to produce serum concentrations similar to treatment doses in infants and young children based on retrospective pharmacokinetic trial of 20 neonates (Acosta 2010; Bradley 2011; CDC 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Full-term neonates (Bautista 2010; Bradley 2011; CDC 2011; WHO 2010): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PNA 0 to 13 days: Limited data available: Oral: 3 mg/kg/dose once daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PNA 14 to 28 days: Oral: 3 mg/kg/dose twice daily for 5 days </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049049\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">see &quot;Oseltamivir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Influenza, treatment:</b> <b>Note:</b> Treatment should ideally begin within 48 hours; however, initiation after 48 hours may decrease mortality or duration of illness. Hospitalized patients may require longer (eg, &ge;10 days) treatment courses. Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza (CDC, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Weight-based dosing (preferred):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CDC Recommendations (independent of HIV status) (CDC 2012; DHHS [pediatric] 2013): Manufacturer's labeling: Oral: 3 mg/kg/dose twice daily for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IDSA/PIDS Recommendations (Bradley 2011): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">1 to 8 months: 3 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">9 to 11 months: 3.5 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Fixed dosing (use <b><span style=\"text-decoration: underline\">only</span></b> if weight not available)</i> (AAP 2010): Limited data available: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&lt;3 months: 12 mg twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">3 to 5 months: 20 mg twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">6 to 11 months: 25 mg twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 12 to 23 months: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CDC Recommendations (independent of HIV status) (CDC 2012; DHHS [pediatric] 2013): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&le;15 kg: 30 mg twice daily for 5 days  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;15 to 23 kg: 45 mg twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;23 kg: See dosage recommendations below for children &ge;2 years</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IDSA/PIDS Recommendations (Bradley 2011): Oral: 3.5 mg/kg/dose twice daily; weight-dependent maximum dose: Weight &le;15 kg: 30 mg; Weight &gt;15 to 23 kg: 45 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;2-12 years and Adolescents (independent of HIV status): <b>Note:</b> Manufacturer's labeling consistent with current CDC and IDSA/PIDS recommendations (Bradley 2011; CDC 2012; DHHS [pediatric] 2013): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&le;15 kg: 30 mg twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;15 to 23 kg: 45 mg twice daily for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;23 to 40 kg: 60 mg twice daily for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;40 kg: 75 mg twice daily for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Influenza, prophylaxis: Note:</b> Initiate treatment within 48 hours of contact with an infected individual. Duration of prophylaxis dependent upon type of exposure or outbreak (eg, household exposure vs hospital outbreak); see below for further details.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: Limited data available </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Weight-directed dosing (preferred):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CDC Recommendation (independent of HIV status) (CDC 2012; DHHS [pediatric] 2013): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&lt;3 months: Not recommended unless clinically critical </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">3 to 11 months: 3 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IDSA/PIDS Recommendations (Bradley 2011): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">3 to 8 months: 3 mg/kg/dose once daily </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">9 to 11 months: 3.5 mg/kg/dose once daily  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Fixed dosing (use <b><span style=\"text-decoration: underline\">only</span></b> if weight not available)</i> (AAP 2010): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&lt;3 months: Not recommended unless clinically critical</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">3 to 5 months: 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">6 to 11 months: 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 12 to 23 months: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CDC Recommendations (independent of HIV status) (CDC 2012; DHHS [pediatric] 2013): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&le;15 kg: 30 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;15 to 23 kg: 45 mg dose once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;23 kg: See dosage recommendations below for weight.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IDSA/PIDS Recommendations (Bradley 2011): Oral: 3.5 mg/kg/dose once daily; weight-dependent maximum dose: Weight: &le;15 kg: 30 mg; Weight &gt;15 to 23 kg: 45 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 2 to 12 years and Adolescents (independent of HIV status): <b>Note:</b> Manufacturer&rsquo;s labeling consistent with current CDC and IDSA/PIDS recommendations (Bradley 2011; CDC 2012; DHHS [pediatric] 2013): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&le;15 kg: 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;15 kg to &le;23 kg: 45 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;23 kg to &le;40 kg: 60 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&gt;40 kg: 75 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Prophylaxis duration:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Individual/household exposure:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Manufacturer labeling: 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Alternate recommendations: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Non-HIV-exposed/-positive: 7 days (CDC 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">HIV-exposed/-positive: 10 days for household exposure; 7 days for other exposures (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Community/institutional outbreak:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Manufacturer recommendation: May be used for up to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Alternate recommendations: Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient (CDC 2012) or until influenza activity in community subsides or immunity obtained from immunization (Bradley 2011). During community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Influenza, prophylaxis:</b> Oral: 75 mg once daily; initiate prophylaxis within 48 hours of contact with an infected individual; duration of prophylaxis: 10 days (manufacturer recommendation) or alternatively 7 days (CDC, 2012). During community outbreaks, duration of protection lasts for length of dosing period; safety and efficacy have been demonstrated for use up to 6 weeks in immunocompetent patients and safety has been demonstrated for use up to 12 weeks in patients who are immunocompromised.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prophylaxis (institutional outbreak; CDC 2012): Continue for &ge;2 weeks and until ~7 days after identification of illness onset in the last patient</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Influenza, treatment:</b> Oral: 75 mg twice daily initiated within 48 hours of onset of symptoms; duration of treatment: 5 days. However, optimal duration is uncertain for severe or complicated influenza. Consider longer duration (eg, &gt;5 days) of therapy in severely ill patients who remain severely ill after 5 days of therapy.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Data  suggest that increased doses (&gt;150 mg daily) in critically ill patients is not necessary since blood concentrations of oseltamivir were comparable or higher compared to ambulatory patients given similar dosing regimens (Ariano 2010; CDC [Influenza Antiviral Medications] 2014). Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza regardless of the time of presentation from symptom onset (even if &gt;48 hours) (CDC [Influenza Antiviral Medications] 2014); may be administered via naso- or orogastric tube in mechanically ventilated patients (Taylor 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;1 year: <b>Treatment</b> (Schreuder 2010): Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent hemodialysis (IHD) (CrCl &le;10 mL/minute): Fixed dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&le;15 kg: 7.5 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;15 kg to &le;23 kg: 10 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;23 kg to &le;40 kg: 15 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;40 kg: 30 mg after each hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &gt;30 to 60 mL/minute: 30 mg twice daily for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &gt;10 to 30 mL/minute: 30 mg once daily for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">End-stage renal disease (ESRD) not undergoing dialysis: Use is not recommended (has not been studied). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Intermittent hemodialysis (IHD) (CrCl &le;10 mL/minute): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Manufacturer labeling: 30 mg after every hemodialysis session for 5 days. <b>Note:</b> Assumes three hemodialysis sessions in the 5-day period. Treatment may be initiated immediately if influenza symptoms develop during the 48 hours between hemodialysis sessions; however, the posthemodialysis dose should still be administered independently of the time of the initial dose administration. </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Alternate recommendations (AMMI Canada [Aoki 2012]): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Low-flux hemodialysis: 30 mg after each dialysis session for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">High-flux hemodialysis: 75 mg after each dialysis session for 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CAPD: 30 mg for one dose to provide a 5-day duration. Administer immediately after a dialysis exchange</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (high-flux): Limited data available: 30 mg once daily for 5 days or 75 mg every 48 hours to provide a 5-day duration (AMMI Canada [Aoki, 2012]; Ariano, 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous veno-venous hemodialysis (CVVHD): <b>Note:</b> Limited data available; optimal dosing has not been established: 150 mg twice daily administered via nasogastric or postpyloric feeding tube for suspected or confirmed H1N1 influenza demonstrated supratherapeutic oseltamivir carboxylate concentrations at effluent rates of 3,300 &plusmn; 919 mL/hour; the authors determined that the manufacturer recommended dosage of 75 mg once daily for patients with CrCl 10 to 30 mL/minute will likely achieve concentrations necessary to inhibit viral neuraminidase activity at these effluent rates; however, doses greater than 75 mg once daily may be required when using higher effluent rates (Eyler, 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">\n      <i>CVVHD and concurrent use of ECMO:</i> Lower oseltamivir carboxylate concentrations (~981 ng/mL) were observed as compared to those with the use of CVVHD alone (~2,760 ng/mL) when patients were administered 150 mg twice daily for suspected or confirmed H1N1 influenza (n=4; Eyler 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &gt;30 to 60 mL/minute: 30 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &gt;10 to 30 mL/minute: 30 mg every other day </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">ESRD not undergoing dialysis: Use is not recommended (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Intermittent hemodialysis (IHD) (CrCl &le;10 mL/minute): 30 mg once after alternate hemodialysis sessions for the recommended prophylaxis duration. <b>Note:</b> An initial dose may be administered prior to the start of dialysis. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CAPD: 30 mg once weekly for the recommended prophylaxis duration. Administer immediately after a dialysis exchange. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (high-flux): No data (AMMI Canada [Aoki 2012]) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild to moderate impairment (Child-Pugh score &le;9): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe impairment: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204091\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tamiflu: 30 mg, 45 mg, 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg, 45 mg, 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tamiflu: 6 mg/mL (60 mL) [contains saccharin sodium, sodium benzoate, sorbitol; tutti-frutti flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/mL (60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204077\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049059\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May administer with or without food; may decrease stomach upset if administered with food </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: May be opened and mixed with sweetened liquid [eg, chocolate syrup,  corn syrup, caramel topping, or light brown sugar (dissolved in water)]. May be administered via naso- or orogastric tube in mechanically ventilated patients; for a 150 mg dose (in adults), dissolve powder from two 75 mg capsules in 20 mL of sterile water and inject down the NG/OG tube; follow with a 10 mL sterile water flush (Taylor 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension: Shake suspension well before use; measure dose in calibrated oral syringe; the manufacturer provided oral syringe should not be used to measure the dose for infants (&lt;1 year of age); a smaller total volume syringe (ie, &lt;10 mL) should be used to accurately measure dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204111\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral suspension: Store powder for suspension at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Once reconstituted, store oral suspension under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or at room temperature; do not freeze. Use within 10 days of preparation if stored at room temperature or within 17 days of preparation if stored under refrigeration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049058\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of influenza infection in patients who have been symptomatic for no more than 2 days (FDA approved in ages &ge;2 weeks and adults); prophylaxis of influenza exposures (FDA approved in ages &ge;1 year and adults)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Has also been used for prophylaxis of influenza in ages &lt;1 year and treatment of patients symptomatic for &gt;2 days with severe illness (CDC, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends that antiviral <b>treatment</b> be considered for the following (see specific antiviral product monograph for appropriate patient selection): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons with severe, complicated or progressive illness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized persons</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons at higher risk for influenza complications</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Children &lt;2 years of age (highest risk in children &lt;6 months of age)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Adults &ge;65 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-\tPersons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate to severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Pregnant or postpartum women (&le;2 weeks after delivery)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons &lt;19 years of age on long-term aspirin therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- American Indians and Alaskan Natives</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons who are morbidly obese (BMI &ge;40)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Residents of nursing homes or other chronic care facilities</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Use may also be considered for previously healthy, non-high-risk outpatients with confirmed or suspected influenza based on clinical judgment when treatment can be started within 48 hours of illness onset. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The ACIP recommends that <b>prophylaxis</b> be considered for the following (<b>Note</b>: Postexposure chemoprophylaxis is generally only recommended when it can be started within 48 hours of most recent exposure) (see specific antiviral product monograph for appropriate patient selection):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications, and who have not been vaccinated against the circulating strain at the time of the exposure or if exposure occurred within 2 weeks of vaccination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications and who cannot be otherwise protected at times of high risk for exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The ACIP recommends that treatment and prophylaxis be given to children &lt;1 year of age when indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamiflu&reg; oral suspension: 75 mg dose delivers 2 g sorbitol </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hospitalized patients with severe 2009 H1N1 influenza infection may require longer (eg, &ge;10 days) treatment courses. Some experts also recommend empirically doubling the treatment dose. Doubling the dose in adult outpatients was not associated with increased adverse events. As no double dose studies have been published in children, use caution. Initiate as early as possible in any hospitalized patient with suspected/confirmed influenza [interim recommendations (CDC, 2010)]. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The absence of symptoms does not rule out viral influenza infection and clinical judgment should guide the decision for therapy. Treatment should not be delayed while waiting for the results of diagnostic tests. Treatment should be considered for high-risk patients with symptoms despite a negative rapid influenza test when the illness cannot be contributed to another cause. Use of oseltamivir is not a substitute for vaccination (when available); susceptibility to influenza infection returns once therapy is discontinued. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204146\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tamiflu may be confused with Tambocor, Thera-Flu</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oseltamivir (Tamiflu) oral suspension is available in a 6 mg/mL concentration. <b>Instructions to the patient should be provided based on these units of measure (ie, mL). When providing oseltamivir suspension for children &lt;1 year of age, use a lower calibrated (ie, &lt;10 mL) oral syringe to ensure accurate dosing.</b></p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">When commercially-prepared oseltamivir oral suspension is not available, an extemporaneously prepared suspension may be compounded to provide a 6 mg/mL concentration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204143\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (adolescents and adults), pain (adolescents and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea (adolescents and adults), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal behavior, abnormal hepatic function tests, accidental injury, anaphylaxis, cardiac arrhythmia, confusion, delirium, delusions, erythema multiforme, gastrointestinal hemorrhage, hallucination, hemorrhagic colitis, hepatitis, hypersensitivity reaction, impaired consciousness, seizure, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204096\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to oseltamivir or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204081\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity: Rare but severe hypersensitivity reactions, including anaphylaxis and severe dermatologic reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme), have been associated with use. Discontinue use immediately if hypersensitivity occurs or is suspected and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric events: Rare occurrences of neuropsychiatric events (including confusion, delirium, hallucinations, and/or self-injury) have been reported primarily in pediatric patients from postmarketing surveillance; direct causation is difficult to establish (influenza infection may also be associated with behavioral and neurologic changes, in some cases resulting in fatal outcomes). These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease. Monitor closely for signs of any unusual behavior.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with chronic cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; safety and efficacy have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; dosage adjustment is required for patients with renal impairment. Not recommended for patients with end stage renal disease (ESRD) not undergoing dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sorbitol: Oral suspension contains sorbitol (delivers ~2 g sorbitol per 75 mg dose) which is greater than the maximum daily limit for patients with hereditary fructose intolerance; may cause diarrhea and dyspepsia; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Oseltamivir is not a substitute for the influenza virus vaccine. It has not been shown to prevent primary or concomitant bacterial infections that may occur with influenza virus. Antiviral treatment should begin within 48 hours of symptom onset. However, the CDC recommends that treatment may still be beneficial and should be started in hospitalized patients with severe, complicated or progressive illness if &gt;48 hours. Treatment should not be delayed while awaiting results of laboratory tests for influenza. Nonhospitalized persons who are not at high risk for developing severe or complicated illness and who have a mild disease are not likely to benefit if treatment is started &gt;48 hours after symptom onset. Nonhospitalized persons who are already beginning to recover do not need treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299796\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204086\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12662&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase serum concentrations of the active metabolite(s) of Oseltamivir. Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204088\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204099\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in some animal reproduction studies. Oseltamivir phosphate and its active metabolite oseltamivir carboxylate cross the placenta (Meijer 2012). An increased risk of adverse neonatal or maternal outcomes has generally not been observed following maternal use of oseltamivir during pregnancy (CDC 60[1] 2011; CDC March 13, 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Neuraminidase inhibitors are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks' postpartum (CDC 60[1] 2011; CDC March 13, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049055\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function, serum glucose in patients with diabetes mellitus; signs or symptoms of unusual behavior, including attempts at self-injury, confusion, and/or delirium</p>\n    <p style=\"text-indent:0em;\">Critically ill patients: Repeat rRT-PCR or viral culture may help to determine ongoing viral replication</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204080\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oseltamivir, a prodrug, is hydrolyzed to the active form, oseltamivir carboxylate (OC). OC inhibits influenza virus neuraminidase, an enzyme known to cleave the budding viral progeny from its cellular envelope attachment point (neuraminic acid) just prior to release.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204095\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Concurrent use of extracorporeal membrane oxygenation (ECMO): When used alone, ECMO has been shown not to impact oseltamivir carboxylate C<sub>max</sub> and AUC in 2 small studies (Lemaitre 2012; Mulla 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 23 to 26 L (oseltamivir carboxylate); may be significantly increased in patients receiving ECMO (Lemaitre 2012; Mulla 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: Oseltamivir carboxylate: 3%; Oseltamivir: 42% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (90%) to oseltamivir carboxylate; neither the parent drug nor active metabolite has any effect on the cytochrome P450 system</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 75% as oseltamivir carboxylate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oseltamivir: 1 to 3 hours; Oseltamivir carboxylate: 6 to 10 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&gt;99% as oseltamivir carboxylate); feces (&lt;20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597869\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Children &le;12 years of age clear the prodrug and active metabolite faster than adult patients, resulting in a lower exposure to a given mg/kg dose. The pharmacokinetics of the prodrug in patients &gt;12 years of age are similar to adult patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5383847\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If the commercially prepared oral suspension is not available, the manufacturer provides the following compounding information to prepare a <b>6 mg/mL</b> suspension in emergency situations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">1. Place the specified amount of water into a polyethyleneterephthalate (PET) or glass bottle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2. Carefully separate the capsule body and cap and pour the contents of the required number of 75 mg capsules into the PET or glass bottle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3. Gently swirl the suspension to ensure adequate wetting of the powder for at least 2 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4. Slowly add the specified amount of vehicle to the bottle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">5. Close the bottle using a child-resistant cap and shake well for 30 seconds to completely dissolve the active drug.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6. Label &ldquo;Shake Well Before Use.&rdquo;</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Stable for 35 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or 5 days at 25&deg; C (77&deg;F). Alternate recommendations suggest that preparations made with water containing preservative (ie, 0.05% sodium benzoate) are stable for 49 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and 10 days at 25&deg;C (77&deg;F) (Tamiflu Canadian product labeling 2017). Shake gently prior to use. Do <b>not</b> dispense with dosing device provided with commercially-available product.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Preparation of Oseltamivir 6 mg/mL Suspension</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Body Weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Total Volume per Patient<sup>1</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\"># of 75 mg Capsules<sup>2</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Required Volume of Water</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Required Volume of Vehicle<sup>2,3</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Treatment Dose (wt based)<sup>4</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Prophylactic Dose (wt based)<sup>4</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"7\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>1</sup>Entire course of therapy.</p></td></tr>\n        <tr>\n          <td colspan=\"7\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>2</sup>Based on total volume per patient.</p></td></tr>\n        <tr>\n          <td colspan=\"7\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>3</sup>Acceptable vehicles are cherry syrup (Humco&reg;), Ora-Sweet&reg; SF, or simple syrup.</p></td></tr>\n        <tr>\n          <td colspan=\"7\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>4</sup>Using 6 mg/mL suspension.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;15 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">69 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mL (30 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mL (30 mg) once daily for 10 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16 to 23 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">91 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mL (45 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mL (45 mg) once daily for 10 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">24 to 40 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">115 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mL (60 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mL (60 mg) once daily for 10 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;41 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">137 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.5 mL (75 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.5 mL (75 mg) once daily for 10 days</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:0em;margin-top:4em;\">\n      <b>Alternate recommendations (</b>\n      <b>Tamiflu Canadian product labeling 2017)<b>:</b></b></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Preparation of Oseltamivir 6 mg/mL Suspension: (using water with preservative [ie, 0.05% sodium benzoate])</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Body Weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Total Volume per Patient<sup>1</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\"># of 75 mg Capsules<sup>2 </sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Required Volume of Water (with preservative)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Treatment Dose (wt based)<sup>2,3</sup></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Prophylactic Dose (wt based)<sup>2,3</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"6\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>Entire course of therapy.</p></td></tr>\n        <tr>\n          <td colspan=\"6\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>2</sup>Using 6 mg/mL suspension.</p></td></tr>\n        <tr>\n          <td colspan=\"6\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>3</sup>Measured dose should be mixed with an equal amount of sweetened liquid (eg, chocolate syrup, cherry syrup) to mask bitter taste.</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;15 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">75 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">74 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mL (30 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 mL (30 mg) once daily for 10 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16 to 23 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">98 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mL (45 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5 mL (45 mg) once daily for 10 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">24 to 40 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">123 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mL (60 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mL (60 mg) once daily for 10 days</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;41 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">147 mL</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.5 mL (75 mg) twice daily for 5 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.5 mL (75 mg) once daily for 10 days</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204098\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Oseltamivir Phosphate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (10): $141.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (10): $141.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (10): $154.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tamiflu Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (10): $167.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (10): $167.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (10): $182.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Oseltamivir Phosphate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (60 mL): $163.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Tamiflu Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (60 mL): $182.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204102\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antiflu (BD, IN);</li>\n      <li>Ao Er Fei (CN);</li>\n      <li>Ebilfumin (CZ, IE, MT);</li>\n      <li>Fluvir (IN);</li>\n      <li>GPO-A-Flu (TH);</li>\n      <li>Omiflu (BD, MY);</li>\n      <li>Oseflu (BD);</li>\n      <li>Pandeflu (BD);</li>\n      <li>Tamiflu (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VN, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acosta EP, Jester P, Gal P, et al, &quot;Oseltamivir Dosing for Influenza Infection in Premature Neonates,&quot; <i>J Infect Dis</i>, 2010, 202(4):563-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/20594104/pubmed\" target=\"_blank\" id=\"20594104\">20594104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aoki FY, Allen UD, Stiver HG, Evans GA. AMMI Canada Guidelines. The use of antiviral drugs for influenza: guidance for practitioners 2012/2013. Can J Infect Dis Med Microbiol. 2012;23(4):e79-92. Available at http://www.ammi.ca/media/48038/14791_aoki_final.pdf.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ariano RE, Sitar DS, Zelenitsky SA, Z, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. <i>CMAJ</i>. 182(4):357-363.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/20159892/pubmed\" target=\"_blank\" id=\"20159892\">20159892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Antiviral Agents For the Treatment and Prophylaxis of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo; <i>MMWR Recomm Rep</i>, 2011, 60 (RR-1): 1-25.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC health update regarding treatment of patients with influenza with antiviral medications. January 9, 2015. Available at  <a href=\"http://emergency.cdc.gov/han/han00375.asp%20\" target=\"_blank\">http://emergency.cdc.gov/han/han00375.asp </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Influenza Antiviral Medications: Summary for Clinicians.&rdquo; Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Accessed on December 18, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Intensive-Care Patients with Severe Novel Influenza A (H1N1) Virus Infection,&rdquo; July, 17, 2009. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5827a4.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Center for Disease Control and Prevention, &quot;Interim Guidance on the Use of Influenza Antiviral Agents During the 2010-2011 Influenza Season, December 15, 2010.&quot; Available at <a href=\"http://www.cdc.gov/flu/professionals/antivirals/index.htm\" target=\"_blank\">http://www.cdc.gov/flu/professionals/antivirals/index.htm</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eyler RF, Heung M, Pleva M, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.  <i>Pharmacotherapy</i>. 2012;32(12):1061-1069.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/23208833/pubmed\" target=\"_blank\" id=\"23208833\">23208833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harper SA, Bradley JS, Englund JA, et al, &quot;Seasonal Influenza in Adults and Children - Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2009, 48(8):1003-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/19281331/pubmed\" target=\"_blank\" id=\"19281331\">19281331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hayden FG, Atmar RL, Schilling M, et al, &ldquo;Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza,&rdquo; <i> N Engl J Med</i>, 1999, 341(18):1336-43. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/10536125/pubmed\" target=\"_blank\" id=\"10536125\">10536125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Shalabi M, Abzug MJ, et al, &quot;Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age,&quot; <i>Pediatr Infect Dis J</i>, 2009, Nov 25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/19949363/pubmed\" target=\"_blank\" id=\"19949363\">19949363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemaitre F, Luyt CE, Roullet-Renoleau F, et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. <i>Ther Drug Monit</i>. 2012;34(2):171-175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/22354159 /pubmed\" target=\"_blank\" id=\"22354159 \">22354159 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Louie JK, Jamieson DJ, Rasmussen SA, et al, &quot;2009 Pandemic Influenza A (H1N1) Virus Infection in Postpartum Women in California,&quot; <i>Am J Obstet Gynecol</i>, 2011, 204(2):144.e1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/21074132/pubmed\" target=\"_blank\" id=\"21074132\">21074132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meijer WJ, Bruinse HW, van den Broek MP, Kromdijk W, Wensing AM. Oseltamivir and its active metabolite cross the placenta at significant levels. <i>Clin Infect Dis</i>. 2012;54(11):1676-1677.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/22460968 /pubmed\" target=\"_blank\" id=\"22460968 \">22460968 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulla H, Peek GJ, Harvey C, Westrope C, Kidy Z, Ramaiah R. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.<i> Anaesth Intensive Care</i>. 2013;41(1):66-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/23362894 /pubmed\" target=\"_blank\" id=\"23362894 \">23362894 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robson R, Buttimore A, Lynn K, et al, &quot;The Pharmacokinetics and Tolerability of Oseltamivir Suspension in Patients on Haemodialysis and Continuous Ambulatory Peritoneal Dialysis,&quot; <i>Nephrol Dial Transplant</i>, 2006, 21(9):2556-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/16799169/pubmed\" target=\"_blank\" id=\"16799169\">16799169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schreuder MF, van der Flier M, Knops NB, et al, &quot;Oseltamivir Dosing in Children Undergoing Hemodialysis,&quot; <i>Clin Infect Dis</i>, 2010, 50(10):1427-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/20397934/pubmed\" target=\"_blank\" id=\"20397934\">20397934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor WRJ, Thinh BN, Anh GT, et al, &ldquo;Oseltamivir is Adequately Absorbed Following Nasogastric Administration to Adult Patients With Severe H5N1 Influenza,&rdquo; <i>PLoS One</i>, 2008, 3(10):e3410.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/18923671/pubmed\" target=\"_blank\" id=\"18923671\">18923671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treanor JJ, Hayden FG, Vrooman PS, et al, &ldquo;Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial. US Oral Neuraminidase Study Group,&rdquo; <i>JAMA</i>, 2000, 283(8):1016-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/ 10697061 /pubmed\" target=\"_blank\" id=\" 10697061 \"> 10697061 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitley RJ, Hayden FG, Reisinger KS, et al, &quot;Oral Oseltamivir Treatment of Influenza in Children,&quot; <i>Pediatr Infect Dis J</i>, 2001, 20(2):127-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/11224828/pubmed\" target=\"_blank\" id=\"11224828\">11224828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, et al, &quot;Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection,&quot; <i>N Engl J Med</i>, 2010, 362(18):1708-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oseltamivir-pediatric-drug-information/abstract-text/20445182/pubmed\" target=\"_blank\" id=\"20445182\">20445182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &ldquo;WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and Other Influenza Viruses.&rdquo; Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12662 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50907063\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204115\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F204116\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049056\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444085\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049049\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204091\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F204077\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049059\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F204111\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049058\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F204146\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204143\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204096\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204081\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299796\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204086\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204088\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204099\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049055\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204080\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F204095\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597869\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F5383847\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F204098\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F204102\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12662|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">Oseltamivir: Drug information</a></li><li><a href=\"topic.htm?path=oseltamivir-patient-drug-information\" class=\"drug drug_patient\">Oseltamivir: Patient drug information</a></li></ul></div></div>","javascript":null}